A phase II trial of neoadjuvant cisplatin–fluorouracil followed by postoperative intraperitoneal floxuridine–leucovorin in patients with locally advanced gastric cancer
Authors:
- M.S. KarpehMKM.S. Karpeh
- M.F. BrennanMBM.F. Brennan
- D.P. KelsenDKD.P. Kelsen
- 20 June 2006
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (9) , 1404-1411
Abstract
Background: The aim of the study was to evaluate the efficacy and toxicity of neoadjuvant chemotherapy with intravenous (i.v.) cisplatin and fluorouracil (5-FU), surgery and postoperative intraperitoneal (i.p.) floxuridine (FUdR) and leucovorin (LV) in patients with locally advanced gastric cancer. Patients and methods: Preoperative staging was confirmed by laparoscopy (LAP). Two cycles of i.v. cisplatin (20 mg/m2/day, rapid infusion) and 5-FU (1000 mg/m2, continuous 24-h infusion), given on days 1–5 and 29–34, were followed by a radical gastrectomy and a D2 lymphadenectomy. Patients having R0 resections were to receive three cycles of i.p. FUdR (1000 mg/m2) and LV (240 mg/m2), given on days 1–3, 15–17 and 29–31. Intraperitoneal chemotherapy was begun 5–10 days from surgery. Results: Thirty-eight patients were treated. Both preoperative and postoperative chemotherapy were well tolerated. T stage downstaging (pretreatment LAP versus surgical pathological stage) was seen in 23% of patients. The R0 resection rate was 84%. Neither an increase in postoperative morbidity nor operative mortality was noted. With a median follow-up of 43.0 months, 15 patients (39.5%) are still alive (median survival 30.3 months). Good pathologic response, seen in five patients (15%), was associated with better survival (P = 0.053). Peritoneal and hepatic failures were found in 22% and 9% of patients, respectively. Quality of life seemed to be preserved. Conclusions: Neoadjuvant cisplatin/5-FU followed by postoperative i.p. FUdR/LV can be safely delivered to patients undergoing radical gastrectomy and D2 lymphadenectomy. The R0 resection and the survival rates are encouraging. An association between pathologic response and patient outcome was suggested.Keywords
This publication has 28 references indexed in Scilit:
- Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971)Journal of Clinical Oncology, 2005
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Intraperitoneal Therapy for Stage III Ovarian Cancer: A Therapy Whose Time Has Come!Journal of Clinical Oncology, 2002
- Postoperative adjuvante Chemoradiotherapie beim HochrisikomagenkarzinomDer Chirurg, 2002
- Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal JunctionNew England Journal of Medicine, 2001
- Cancer burden in the year 2000. The global pictureEuropean Journal of Cancer, 2001
- The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomyCancer, 2000
- A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancerCancer, 1994
- Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1982